PriceTargets.com logo

Dechra Pharmaceuticals - DCHPF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$46.90 As of 01/18/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for DCHPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dechra Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCHPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCHPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Dechra Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $46.90.

This chart shows the closing price for DCHPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Dechra Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/27/2023Stifel NicolausDowngradeBuy ➝ Hold
3/7/2023JPMorgan Chase & Co.Lower TargetGBX 4,600 ➝ GBX 4,000
1/12/2023Panmure GordonUpgradeHold ➝ Buy
1/10/2023Liberum CapitalUpgradeHold ➝ Buy
1/3/2023JPMorgan Chase & Co.Lower TargetGBX 5,700 ➝ GBX 4,600
10/18/2022Jefferies Financial GroupUpgradeHold ➝ Buy
10/5/2022Berenberg BankInitiated CoverageHold
9/15/2022Royal Bank of CanadaLower TargetGBX 4,200 ➝ GBX 4,000
7/11/2022Panmure GordonDowngradeBuy ➝ Hold
7/5/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
2/23/2022Liberum CapitalUpgradeSell ➝ Hold
2/21/2022Panmure GordonUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.Boost TargetGBX 5,400 ➝ GBX 5,700
9/7/2021JPMorgan Chase & Co.Reiterated RatingOverweight
9/6/2021Stifel NicolausDowngradeBuy ➝ Hold
7/13/2021JPMorgan Chase & Co.Reiterated RatingOverweight
3/11/2021Royal Bank of CanadaReiterated RatingSector Perform
11/20/2020Royal Bank of CanadaReiterated RatingSector Perform
10/7/2019Jefferies Financial GroupDowngradeBuy ➝ Hold
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Dechra Pharmaceuticals logo
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More

Today's Range

Now: $46.90
Low: $46.90
High: $46.90

50 Day Range

MA: $46.90
Low: $46.90
High: $46.90

52 Week Range

Now: $46.90
Low: $30.00
High: $47.40

Volume

N/A

Average Volume

1,687 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dechra Pharmaceuticals?

The following equities research analysts have issued research reports on Dechra Pharmaceuticals in the last twelve months: Stifel Nicolaus.
View the latest analyst ratings for DCHPF.

What is the current price target for Dechra Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Dechra Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Dechra Pharmaceuticals in the next year.
View the latest price targets for DCHPF.

What is the current consensus analyst rating for Dechra Pharmaceuticals?

Dechra Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DCHPF, but not buy more shares or sell existing shares.
View the latest ratings for DCHPF.

What other companies compete with Dechra Pharmaceuticals?

Other companies that are similar to Dechra Pharmaceuticals include AstraZeneca, Cosmo Pharmaceuticals, CSPC Pharmaceutical Group, Daiichi Sankyo and JCR Pharmaceuticals. Learn More about companies similar to Dechra Pharmaceuticals.

How do I contact Dechra Pharmaceuticals' investor relations team?

Dechra Pharmaceuticals' physical mailing address is Cheshire Business Park, Northwich, Cheshire CW9. The company's listed phone number is 441606814730. The official website for Dechra Pharmaceuticals is dechra.com. Learn More about contacing Dechra Pharmaceuticals investor relations.